P2RY2 and cystic fibrosis: Oxo-AHLs treatments repressed the stimulatory effects of secretory leukocyte proteinase inhibitor secretion by nucleotides, possibly due to the repression of P2Y2 and P2Y4 receptor expression, in cystic fibrosis but not normal HTGS cells [68].